Tango Therapeutics (TNGX)
Develops MTAP-selective PRMT5 inhibitors for genetically defined cancers.
Something off on this page? Send us feedback.
Develops biomarker-selected cancer drugs built around synthetic lethality, led by vopimetostat combinations for MTAP-deleted pancreatic and lung cancers and brain-penetrant TNG456 for glioblastoma. Has no approved products or product sales; progress depends on clinical results, regulatory clearance, collaborators, and outsourced manufacturing.
Develops precision-oncology drugs for genetically defined cancers by pairing synthetic-lethality target discovery with biomarker-selected clinical trials. The lead program, vopimetostat, is an MTAP-selective PRMT5 inhibitor in clinical development alone and with RAS-targeted therapies for pancreatic and lung cancers; the daraxonrasib combination is moving toward late-stage planning.
A second PRMT5 candidate, TNG456, is designed to reach the brain and is being tested in MTAP-deleted glioblastoma and other solid tumors. The broader pipeline includes TNG260, a CoREST inhibitor for a genetically defined lung-cancer subgroup, and the preclinical HBS1L degrader TNG961.
Operates as a clinical-stage biotechnology business without approved products or product sales. Progress depends on trial outcomes, regulatory approval, collaboration partners including Revolution Medicines and Erasca, and third-party clinical and manufacturing providers.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 18, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $66 | Target: $68 |
| Aug 12, 2026 | Guggenheim | Reiterate | Rating: —Target: $12 | Target: $35 |
| Jul 17, 2026 | Mizuho Securities | Target | Target: $36 | Target: $40 |
| Jun 29, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $42 | Target: $46 |
| Jun 26, 2026 | Jefferies | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.01B · Total debt $32.0M · Total assets $1.07B · Shareholders' equity $1.02B
- Revenue
- $0
- Operating income
- −$59.8M
- Net income
- −$55.3M
No dividends on record.
| Institutions | ≈ 125.12% | 210.96M shares | |
|---|---|---|---|
| 259 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 12.90% | 21.76M shares | |
| 14 holders · as of Sep 3, 2026 | |||
| Strategic holders | 6.88% | 11.60M shares | |
| 1 holder · as of May 15, 2026 | |||
| Adds to | 144.90% | ||
168.61M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 144.90%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
RTW Investments, LPInstitution | 8.24% | 13.90M | as of Jun 30, 2026 |
TCG Crossover GP II, L.P.Insider | 8.02% | 13.52M | filed Feb 17, 2026 |
Adage Capital Management, L.P.Institution | 7.60% | 12.81M | filed May 13, 2026 |
BlackRock, Inc.Institution | 7.38% | 12.44M | as of Jun 30, 2026 |
FMR LLCInstitution | 7.31% | 12.33M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 1, 2026 | Adam Crystal | officer: President, R&D | −27,000 | $22.37 |
| Aug 3, 2026 | Adam Crystal | officer: President, R&D | −27,000 | $27.24 |
| Jul 1, 2026 | Adam Crystal | officer: President, R&D | −27,000 | $29.59 |
| Jun 1, 2026 | Adam Crystal | officer: President, R&D | −27,000 | $22.87 |
| May 1, 2026 | Adam Crystal | officer: President, R&D | −27,000 | $21.23 |
- Bristol-Myers Squibb
Most direct PRMT5-MTA benchmark in MTAP-deleted solid tumors
- Amgen
Clinical PRMT5 peer with AMG 193 in MTAP-deleted tumors
- IDEAYA Biosciences
MTAP pathway peer spanning MAT2A and PRMT5 programs
- AstraZeneca (ADR)
Big-pharma PRMT5 entrant with AZD3470 in MTAP-deficient tumors
- BeOne Medicines (ADR)
PRMT5 and MAT2A oncology peer in MTAP-deficient tumors
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Tango Therapeutics | $23.65 | +5.91% | $3.64B | — | — | 67.6 | +363.6% |
| Bristol-Myers Squibb | $62.79 | +0.26% | $127.91B | 13.8 | 9.8 | 2.6 | +5.7% |
| Amgen | $401.35 | +2.08% | $212.19B | 24.4 | 17.1 | 5.6 | +9.7% |
| IDEAYA Biosciences | $38.99 | +0.33% | $3.69B | — | — | 15.8 | — |
| AstraZeneca (ADR) | $167.91 | −0.11% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| BeOne Medicines (ADR) | $361.37 | −1.18% | $39.07B | 5.1 | 45.8 | 6.4 | +29.6% |
| Median | 19.1 | 16.4 | 5.6 | +8.0% |